DaVita (NYSE:DVA) Sets New 1-Year High – Still a Buy?

by · The Cerbat Gem

DaVita Inc. (NYSE:DVA – Get Free Report) reached a new 52-week high on Tuesday . The company traded as high as $169.64 and last traded at $169.73, with a volume of 161278 shares. The stock had previously closed at $166.24.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on DVA shares. Truist Financial lifted their price objective on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Barclays raised their price target on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $161.80.

Read Our Latest Stock Analysis on DVA

DaVita Price Performance

The firm has a market cap of $13.93 billion, a price-to-earnings ratio of 18.32, a P/E/G ratio of 0.81 and a beta of 0.92. The business’s 50-day moving average price is $157.35 and its two-hundred day moving average price is $153.12. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33.

DaVita (NYSE:DVA – Get Free Report) last released its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing the consensus estimate of $2.76 by ($0.17). The company had revenue of $3.26 billion during the quarter, compared to the consensus estimate of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. During the same period in the previous year, the firm posted $2.85 EPS. DaVita’s revenue for the quarter was up 4.6% on a year-over-year basis. On average, research analysts forecast that DaVita Inc. will post 9.71 EPS for the current fiscal year.

Institutional Investors Weigh In On DaVita

A number of institutional investors have recently made changes to their positions in DVA. Transcendent Capital Group LLC bought a new position in shares of DaVita during the third quarter valued at approximately $25,000. Blue Trust Inc. grew its stake in DaVita by 56.4% during the 3rd quarter. Blue Trust Inc. now owns 330 shares of the company’s stock worth $54,000 after buying an additional 119 shares during the last quarter. Quarry LP acquired a new stake in DaVita in the third quarter worth $60,000. Versant Capital Management Inc lifted its stake in DaVita by 58.7% in the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock valued at $68,000 after buying an additional 169 shares during the last quarter. Finally, Point72 Hong Kong Ltd acquired a new position in shares of DaVita during the second quarter valued at $68,000. 90.12% of the stock is currently owned by institutional investors.

DaVita Company Profile

(Get Free Report)

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Featured Stories